New drug cocktail targets rare childhood cancer
NCT ID NCT07328425
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two chemotherapy drugs, lurbinectedin and irinotecan, in 20 patients aged 15 and older with advanced desmoplastic small round cell tumor (DSRCT) that cannot be surgically removed. The goal is to shrink or control the tumor and track side effects. An optional part of the study looks at tumor genes to understand how the cancer behaves and responds to treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DESMOPLASTIC SMALL ROUND CELL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione IRCCS Istituto Nazionale dei Tumori
RECRUITINGMilan, 20133, Italy
-
Fondazione Policlinico Universitario Campus Bio-Medico
RECRUITINGRoma, 00128, Italy
-
Fondazione del Piemonte per l'Oncologia IRCCS
RECRUITINGCandiolo, Torino, 10060, Italy
-
IOV Istituto Oncologico Veneto IRCCS
RECRUITINGPadova, 35128, Italy
-
Nuovo Ospedale "S.Stefano"
RECRUITINGPrato, 59100, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive antibody targets rare childhood cancer
- New immunotherapy targets genetic flaw in rare childhood cancers
- New hope for tough tumors: Half-Matched bone marrow transplant trial
- New drug cocktail aims to keep childhood cancers at bay
- New drug cocktail aims to tackle tough sarcomas in young patients
- New cocktail of four drugs aims to tackle childhood cancers that Won't go away